Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Ryan White HIV/AIDS Program Client-Level Data Reporting System, 57913-57914 [2024-15616]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 136 / Tuesday, July 16, 2024 / Notices
alone pre-existing tobacco product
submissions. We estimate that it would
take 2 hours per record to establish the
required records for a total of 4 hours for
pre-existing products records and SE
exemptions.
Our estimated burden for the
information collection reflects an
overall increase of 369,555 hours and a
corresponding increase of 1,302
responses/records. We attribute this
adjustment to adding a new form, the
validator tool, and reevaluating our
current estimates.
Dated: July 11, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–15570 Filed 7–15–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request; Ryan White HIV/AIDS
Program Client-Level Data Reporting
System
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
Paperwork Reduction Act of 1995,
HRSA submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period. OMB may act on
HRSA’s ICR only after the 30-day
comment period for this notice has
closed.
SUMMARY:
Comments on this ICR should be
received no later than August 15, 2024.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under Review—Open for
Public Comments’’ or by using the
search function.
khammond on DSKJM1Z7X2PROD with NOTICES
DATES:
VerDate Sep<11>2014
16:55 Jul 15, 2024
Jkt 262001
To
request a copy of the clearance requests
submitted to OMB for review, email
Joella Roland, the HRSA Information
Collection Clearance Officer, at
paperwork@hrsa.gov or call (301) 443–
3983.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title:
Ryan White HIV/AIDS Program ClientLevel Data Reporting System, OMB No.
0906–0039—Revision.
Abstract: The Ryan White HIV/AIDS
Program (RWHAP), authorized under
Title XXVI of the Public Health Service
Act, is administered by the HIV/AIDS
Bureau within HRSA. HRSA awards
funding to recipients in areas of the
greatest need to respond effectively to
the HIV epidemic, with an emphasis on
providing life-saving and life-extending
medical care, treatment, and support
services for people with HIV in the
United States.
The RWHAP reporting requirements
include the annual submission of clientlevel data in the RWHAP Services
Report (RSR). The RSR is designed to
collect information from grant recipients
and their subawarded service providers,
funded under Parts A, B, C, and D of the
RWHAP statute.
HRSA is requesting a revision of the
current RSR with two proposed updates:
FOR FURTHER INFORMATION CONTACT:
Health Coverage
• HRSA proposes adding Medicare
Advantage as a response option to the
client’s healthcare coverage data
element.
Drug Addiction Treatment Act of 2000
Waiver Requirement
Current Questions
• Within your organization/agency,
identify the number of physicians, nurse
practitioners, or physician assistants
who obtained a Drug Addiction
Treatment Act of 2000 waiver to treat
opioid use disorder with medication
assisted treatment, (e.g., buprenorphine,
naltrexone) specifically approved by the
U.S. Food and Drug Administration.
• How many of the above physicians,
nurse practitioners, or physician
assistants prescribed medication
assisted treatment (e.g., buprenorphine,
naltrexone) for opioid use disorders in
the reporting period?
Proposed Change to Question in 2024
RSR Form
• How many physicians, nurse
practitioners, or physician assistants in
your organization prescribed
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
57913
medications for opioid use disorder
(e.g., buprenorphine, naltrexone) for
opioid use disorders during the
reporting period?
A 60-day notice published in the
Federal Register on April 24, 2024, vol.
89, No. 79; pp. 30384–85. There were no
public comments.
Need and Proposed Use of the
Information: The RWHAP statute
specifies HRSA’s responsibilities in
administering grant funds, allocating
funding, assessing HIV care outcomes
(e.g., viral suppression), and serving
priority populations. The RSR collects
data on the characteristics of RWHAPfunded recipients, their contracted
service providers, and the patients or
clients served. The RSR system consists
of two primary components (the
Recipient Report and the Provider
Report) and a data file containing deidentified client-level data elements.
Data are submitted annually. The
RWHAP statute specifies the importance
of recipient accountability. The RSR is
used to ensure recipient compliance
with the law, including evaluating the
effectiveness of programs, monitoring
recipient and provider performance, and
preparing annual reports to Congress.
Information collected through the RSR
is critical for HRSA, state and local
grant recipients, and individual
providers to assess the status of existing
HIV-related service delivery systems,
monitor trends in service utilization,
evaluate the impact of data reporting,
and identify areas of greatest need.
Likely Respondents: RWHAP grant
recipients, as well as their subawarded
service providers, funded under
RWHAP Parts A, B, C, and D.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating, and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
E:\FR\FM\16JYN1.SGM
16JYN1
57914
Federal Register / Vol. 89, No. 136 / Tuesday, July 16, 2024 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Total
responses
Average
burden per
response
(in hours)
Total
burden
hours
Recipient Report ..................................................................................
Provider Report ....................................................................................
Client Report ........................................................................................
595
2,063
1,532
1
1
1
595
2,063
1,532
11
13
113
6,545
26,819
173,116
Total ..............................................................................................
4,190
..........................
4,190
....................
206,480
Maria G. Button,
Director, Executive Secretariat.
ACBTSA@hhs.gov. Phone: 202–795–
7608.
[FR Doc. 2024–15616 Filed 7–15–24; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood and Tissue Safety and
Availability
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
The U.S. Department of
Health and Human Services is hereby
giving notice that the Advisory
Committee on Blood and Tissue Safety
and Availability (ACBTSA) will hold a
meeting. The meeting will be open to
the public via webcast. The committee
will discuss and vote on
recommendations related to tissue
biovigilance. The committee will also
hear presentations and updates on
recent committee work related to blood
and organ safety.
DATES: The meeting will take place on
September 4–5, 2024 from
approximately 9:00 a.m.–4:00 p.m.
Eastern Time (ET) on September 4th and
approximately 9:00 a.m.–1:00 p.m.
Eastern Time (ET) on September 5th.
Meeting times are tentative and subject
to change. The confirmed times and
agenda items for the meeting will be
posted on the ACBTSA web page at
https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meeting-summary/fiftyninth-acbtsa-meeting/ when
this information becomes available.
FOR FURTHER INFORMATION CONTACT:
James Berger, Designated Federal Officer
for the ACBTSA; Office of Infectious
Disease and HIV/AIDS Policy, Office of
the Assistant Secretary for Health,
Department of Health and Human
Services, Tower Building, 1101 Wootton
Parkway, Rockville, MD 20852. Email:
SUMMARY:
VerDate Sep<11>2014
16:55 Jul 15, 2024
Jkt 262001
On the
day of the meeting, please go to https://
www.hhs.gov/live/ to view
the meeting. The public will have an
opportunity to present their views to the
ACBTSA by submitting a written public
comment or providing a verbal public
comment during the meeting.
Comments should be pertinent to the
meeting discussion. Persons who wish
to provide written or verbal public
comment should review instructions at
https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meeting-summary/fiftyninth-acbtsa-meeting/ and
respond by midnight August 27, 2024,
ET.
Background and Authority: The
ACBTSA is a discretionary Federal
advisory committee and is governed by
the provisions of the Federal Advisory
Committee Act (FACA), Public Law 92–
463, as amended (5 U.S.C. app), which
sets forth standards for the formation
and use of advisory committees. The
ACBTSA functions to provide advice to
the Secretary through the Assistant
Secretary for Health on a range of policy
issues to include: (1) Identification of
public health issues through
surveillance of blood and tissue safety
issues with national survey and data
tools; (2) identification of public health
issues that affect availability of blood,
blood products, and tissues; (3) broad
public health, ethical, and legal issues
related to the safety of blood, blood
products, and tissues; (4) the impact of
various economic factors (e.g., product
cost and supply) on safety and
availability of blood, blood products,
and tissues; (5) risk communications
related to blood transfusion and tissue
transplantation; and (6) identification of
infectious disease transmission issues
for blood, organs, blood stem cells and
tissues. The Committee has met
regularly since its establishment in
1997.
SUPPLEMENTARY INFORMATION:
BILLING CODE 4165–15–P
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
responses per
respondent
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Dated: July 1, 2024.
James J. Berger,
Designated Federal Officer, Advisory
Committee on Blood and Tissue Safety and
Availability, Office of Infectious Disease and
HIV/AIDS Policy.
[FR Doc. 2024–15566 Filed 7–15–24; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Mentored Career Development KAwards.
Date: August 21, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Zhihong Shan, Ph.D., MD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute National Institutes of Health,
6705 Rockledge Drive, Room 205–J Bethesda,
MD 20892, (301) 827–7085, zhihong.shan@
nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Opportunities for Collaborative Research at
the NIH Clinical Center (U01).
Date: August 28, 2024.
E:\FR\FM\16JYN1.SGM
16JYN1
]]>Agencies
[Federal Register Volume 89, Number 136 (Tuesday, July 16, 2024)]
[Notices]
[Pages 57913-57914]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-15616]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Submission to OMB for
Review and Approval; Public Comment Request; Ryan White HIV/AIDS
Program Client-Level Data Reporting System
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the Paperwork Reduction Act of 1995, HRSA
submitted an Information Collection Request (ICR) to the Office of
Management and Budget (OMB) for review and approval. Comments submitted
during the first public review of this ICR will be provided to OMB. OMB
will accept further comments from the public during the review and
approval period. OMB may act on HRSA's ICR only after the 30-day
comment period for this notice has closed.
DATES: Comments on this ICR should be received no later than August 15,
2024.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under Review--Open for
Public Comments'' or by using the search function.
FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance
requests submitted to OMB for review, email Joella Roland, the HRSA
Information Collection Clearance Officer, at [email protected] or call
(301) 443-3983.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title: Ryan White HIV/AIDS Program
Client-Level Data Reporting System, OMB No. 0906-0039--Revision.
Abstract: The Ryan White HIV/AIDS Program (RWHAP), authorized under
Title XXVI of the Public Health Service Act, is administered by the
HIV/AIDS Bureau within HRSA. HRSA awards funding to recipients in areas
of the greatest need to respond effectively to the HIV epidemic, with
an emphasis on providing life-saving and life-extending medical care,
treatment, and support services for people with HIV in the United
States.
The RWHAP reporting requirements include the annual submission of
client-level data in the RWHAP Services Report (RSR). The RSR is
designed to collect information from grant recipients and their
subawarded service providers, funded under Parts A, B, C, and D of the
RWHAP statute.
HRSA is requesting a revision of the current RSR with two proposed
updates:
Health Coverage
HRSA proposes adding Medicare Advantage as a response
option to the client's healthcare coverage data element.
Drug Addiction Treatment Act of 2000 Waiver Requirement
Current Questions
Within your organization/agency, identify the number of
physicians, nurse practitioners, or physician assistants who obtained a
Drug Addiction Treatment Act of 2000 waiver to treat opioid use
disorder with medication assisted treatment, (e.g., buprenorphine,
naltrexone) specifically approved by the U.S. Food and Drug
Administration.
How many of the above physicians, nurse practitioners, or
physician assistants prescribed medication assisted treatment (e.g.,
buprenorphine, naltrexone) for opioid use disorders in the reporting
period?
Proposed Change to Question in 2024 RSR Form
How many physicians, nurse practitioners, or physician
assistants in your organization prescribed medications for opioid use
disorder (e.g., buprenorphine, naltrexone) for opioid use disorders
during the reporting period?
A 60-day notice published in the Federal Register on April 24,
2024, vol. 89, No. 79; pp. 30384-85. There were no public comments.
Need and Proposed Use of the Information: The RWHAP statute
specifies HRSA's responsibilities in administering grant funds,
allocating funding, assessing HIV care outcomes (e.g., viral
suppression), and serving priority populations. The RSR collects data
on the characteristics of RWHAP-funded recipients, their contracted
service providers, and the patients or clients served. The RSR system
consists of two primary components (the Recipient Report and the
Provider Report) and a data file containing de-identified client-level
data elements. Data are submitted annually. The RWHAP statute specifies
the importance of recipient accountability. The RSR is used to ensure
recipient compliance with the law, including evaluating the
effectiveness of programs, monitoring recipient and provider
performance, and preparing annual reports to Congress. Information
collected through the RSR is critical for HRSA, state and local grant
recipients, and individual providers to assess the status of existing
HIV-related service delivery systems, monitor trends in service
utilization, evaluate the impact of data reporting, and identify areas
of greatest need.
Likely Respondents: RWHAP grant recipients, as well as their
subawarded service providers, funded under RWHAP Parts A, B, C, and D.
Burden Statement: Burden in this context means the time expended by
persons to generate, maintain, retain, disclose, or provide the
information requested. This includes the time needed to review
instructions; to develop, acquire, install, and utilize technology and
systems for the purpose of collecting, validating, and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information; to search data sources; to complete and
review the collection of information; and to transmit or otherwise
disclose the information. The total annual burden hours estimated for
this ICR are summarized in the table below.
[[Page 57914]]
Total Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total burden per Total
Form name respondents responses per responses response burden
respondent (in hours) hours
----------------------------------------------------------------------------------------------------------------
Recipient Report........................... 595 1 595 11 6,545
Provider Report............................ 2,063 1 2,063 13 26,819
Client Report.............................. 1,532 1 1,532 113 173,116
--------------------------------------------------------------------
Total.................................. 4,190 ............... 4,190 ........... 206,480
----------------------------------------------------------------------------------------------------------------
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024-15616 Filed 7-15-24; 8:45 am]
BILLING CODE 4165-15-P
